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Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) have gastrointestinal side effects
such as dyspepsia, peptic ulcer, hemorrhage, and perforation. Misoprostol and PPIs have been
used to prevent NSAID-induced gastroduodenal injury. Rebamipide increases gastric mucus
and stimulates the production of endogenous prostaglandins. The prophylactic effect of
rebamipide on NSAID-induced gastrointestinal complications is unknown. The aim of this
study was to compare NSAID-induced gastrointestinal complications in rebamipide- and
misoprostol-treated groups. Patients were randomized to two groups and took a conventional
NSAID plus rebamipide or misoprostol for 12 weeks. Gastric mucosal damage was evaluated
by endoscopy at screening and the end of the study. The prevalences of active gastric ulcer
were 7/176 (3.9%) in the rebamipide group and 3/156 (1.9%) in the misoprostol group. The
prevalences of peptic ulcer were 8/176 (4.5%) in the rebamipide group and 7/156 (4.4%) in the
misoprostol group. The cumulative incidences of peptic ulcer in the high-risk subgroup were
6/151 (4.0%) for rebamipide and 6/154 (3.9%) for misoprostol. In conclusion, rebamipide
prevented NSAID-induced peptic ulcer as effectively as misoprostol in patients on long-term
NSAID therapy. Rebamipide may be a useful therapeutic option for the prevention of NSAID-
induced gastrointestinal ulcer because of its therapeutic effect and safety.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) contribute
to the management of arthritis and other inflammatory con-
ditions. Upper gastrointestinal (GI) adverse events, ranging
from dyspepsia to life-threatening complications such as
perforation, are the primary side effects associated with
NSAIDs. Gastroprotective agents are therefore often
prescribed concomitantly with NSAIDs. Ulcers can be
documented endoscopically in up to 40% of chronic
NSAID users; however, it is estimated that as many as
85% of these ulcers never become clinically apparent
[1]. Misoprostol and omeprazole, are only prescribed
drugs in decreasing the NSAID-associated GI mucosal
injury. Prophylaxis by gastroprotective agents decreases
ulcer complications associated with long-term NSAID use.
Misoprostol is a synthetic prostaglandin (PG) E1 analogue
that has been shown to be gastroprotective by augmenting
depleted mucosal defense factors and inhibiting gastric acid
secretion. Numerous studies have been performed on the use
of misoprostol to prevent NSAID-induced gastrointestinal
complications. A dose–response study showed that 600 ug
and 800 ug doses of misoprostol yielded similar protective
effects [2]. Misoprostol reduces the risk of endoscopic
ulcers, even at doses of 400, 600, and 800 µg/day [2–4].
However, a high incidence of diarrhea has been reported and
documented in many patients on continuous misoprostol
treatment.
Rebamipide (2-(4-chlorobenzoylamino)-3-[2-(1H)-quinolinon-
4-yl]-propionic acid) (Otsuka Pharmaceutical Co., Tokyo)
is a cytoprotective antiulcer drug that enhances defense
mechanisms in the gastric mucosa by increasing gastric
mucus and stimulating the production of endogenous
prostaglandins, and has been reported to reduce gastric
mucosal injury [5,  6]. The anti-inflammatory effects of
rebamipide are due to its inhibitory effect on the production
of superoxides [7]. Rebamipide significantly accelerated ulcer
healing, in association with the expression of epidermal
growth factor and epidermal growth factor receptor [8].
The efficacy of rebamipide in preventing NSAID-induced
gastric injury has been reported in healthy volunteers on
indomethacin treatment [9]. However, the efficacy of
rebamipide in preventing NSAID-induced gastrointestinal
complications has not been determined. The purpose of this
study was to evaluate the cumulative incidence of NSAID-
induced gastrointestinal complications such as ulcers in
rebamipide- and misoprostol-treated groups in a random-
ized, multicenter, controlled trial.
Methods
Study design
A randomized, multicenter, controlled, open-label trial
was performed in Korea, China, and Thailand. The subjects
were recruited for treatment sequences in random fashion
according to a randomization schedule for the treatment
period from departments of rheumatology and internal
medicine outpatient clinics. Individuals who were at least 18
years of age with rheumatoid arthritis, osteoarthritis, or
ankylosing spondylitis or any other condition that required
continuous NSAID therapy for more than 12 weeks were
included in this study. Exclusion Criteria were as follows:
individuals with a history of a serious medical condition
(chronic liver disease or chronic renal disease); individuals
with any other clinically significant gastrointestinal diseases
confirmed by endoscopy, such as GERD, esophageal varix,
peptic ulcer, or malignancy; those with a history of any
documented gastric surgery or any malignant disease; those
reporting recent use (within 4 weeks prior to the study) of
sucralfate, H2-RA, misoprostol, PPIs, prokinetics, or any
other medications that could affect acid secretion or gastro-
intestinal motility; and those reporting recent use (within 4
weeks prior to the study) of any NSAIDs, corticosteroids,
anticholinergics, antineoplastics, or anticoagulants.
Patients were randomly assigned to receive either 100 mg
rebamipide or 200 µg misoprostol t.i.d. for 12 weeks.
Assessment of dyspepsia using a diary card and compliance
with the trial drug and NSAIDs was performed every 2
weeks until 12 weeks (Fig. 1). Concomitant use of NSAIDs
during this study was limited to aceclofenac, diclofenac,
fenoprofen, ibuprofen, naproxen, and sulindac. Patients with
a rate of compliance of less than 85% with study drugs and
minimum daily dosage of NSAIDs were excluded from the
study. The severity of dyspeptic symptoms was scored on a
four-point scale. The study protocol was approved by the
Ethics Committees of each of the 12 participating hospitals,
and written informed consent was obtained from each of the
patients.
Randomization
Subjects were recruited for the treatment sequences in
random fashion according to a randomization schedule for
the treatment period. A randomization number that was
associated with a specific treatment with either rebamipide
or misoprostol was assigned to each patient included in
the study. The treatment was randomly assigned using an
allocation ratio of 1:1 for the two treatment groups. Patients
were allocated to the next available randomization number
at each center. Allocation of randomized numbers was
performed using the SAS program.
Endoscopic evaluation
Two endoscopists reviewed still images to establish
standardized reporting criteria for ulcers and other lesions.
At endoscopy, video or photographic images were recorded
separately for the esophagus, gastric body, gastric antrum,S.-H. Park et al.
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duodenal bulb, and second part of the duodenum. An ulcer
was defined as an excavated mucosal break 3 mm or more in
diameter, measured with biopsy forceps or a custom-made
device. Erosions were defined as superficial mucosal breaks,
and intramucosal hemorrhages as hemorrhagic lesions
without overlying mucosal breaks. Endoscopic mucosal
damage was evaluated using the modified Lanza score, of 0
to 5, during the screening period and at the end of the study.
Endoscopic diagnoses of subjects were reviewed after the
study by four different endoscopists not participating in
this study. Helicobacter pylori status was determined by
CLO test (Kimberly-Clark Corporation, Irving, TX) during
screening endoscopy.
Unscheduled endoscopy
Subjects who had intractable symptoms of dyspepsia, who
were positive for occult blood in stool, had anemia (more
than 1 g/dL decrease from baseline value of hemoglobin),
hematemesis or hematochezia, or required rescue antacid
consumption for more than 7 days underwent unscheduled
endoscopy to ensure patient safety.
Evaluation of adverse events
Adverse events were of the following categories: (1)
Symptoms of dyspepsia: the following gastrointestinal
symptoms were to be recorded in the symptom diary-fullness,
early satiety, bloating, nausea, vomiting, heartburn, and acid
regurgitation. (2) Gastrointestinal complications, defined as
intractable abdominal pain, intractable diarrhea, and intractable
symptoms of dyspepsia. The criterion for intractable abdominal
pain was moderate pain on the four-point scale lasting more
than 3 days per week. The criterion for intractable diarrhea
was more than 4 per day for more than 3 days per week.
The criterion for intractable symptoms of dyspepsia was
moderate pain on the four-point scale lasting more than 7
days between visits.
End points
The primary endpoint was the cumulative incidence of
gastric or duodenal ulceration at 12 weeks. The secondary
endpoint was the cumulative incidence of adverse events.
Statistical analysis
We referred to the results of a previous clinical trial in
determining the trial size [10]. Equivalence of rebamipide to
Fig. 1. Flow diagram of subjects progress through the studyRebamipide and Misoprostol: Multicenter RCT-STORM
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misoprostol at the primary endpoint was considered demon-
strated when the 95% two-sided confidence intervals of the
difference between the rebamipide and misoprostol groups
was not less than the pre-specified limit of equivalence of −
0.07 and not more than the pre-specified limit of equivalence
of 0.07. A categorical model underlying the confidence
interval with the center and treatment as fixed factors was
used. Laboratory tests, age, sex, H. pylori infection status,
and body weight measurements from pretreatment to post-
treatment were analyzed both within and between the
treatment groups using Student’s unpaired t test or the
Wilcoxon rank-sum test. A shift table with chi-square
analysis of the change in normal range from baseline was
last values over the course of the study. All statistical tests
were two-sided, with a 5% level of significance. In addition,
95% two-sided confidence intervals were used. The SAS
program (Ver. 8.1) was used for statistical analyses.
Results
Demographic characteristics of patients
A total of 456 patients were scheduled to undergo endo-
scopic screening for enrollment in this trial. Forty-six
patients were excluded during the screening period, and 410
patients were enrolled and evaluated (Fig. 2). The numbers
of enrolled patients from China, Korea, and Thailand were
174, 153, and 83, respectively. The treatment groups were
well-balanced with respect to treatment with NSAIDs, sex,
age, and frequency of H. pylori infection (Table 1). The
most commonly used NSAIDs were diclofenac (36.8%),
aceclofenac (34.9%), and naproxen (7.8%) (Table 2).
Evaluation of the incidence of gastrointestinal ulcers and
adverse events included 207 patients in the rebamipide
group and 203 in the misoprostol group. For this analysis,
31 patients were excluded from the rebamipide group and
47 from the misoprostol group because of adverse events,
patient’s request, or other reasons (Fig. 2).
Prevalence of peptic ulcer
The prevalences of gastric ulcer during the 12-week study
period were 7/176 (3.9%) in the rebamipide group and 3/156
(1.9%) in the misoprostol group. The prevalences of
duodenal ulcer were 1/176 (0.5%) in the rebamipide group
and 4/156 (2.5%) in the misoprostol group. Peptic ulcer was
Fig. 2.  Enrollment and randomization of the studied population
Symptoms; Two patients had intractable pain, and 2 were vomiting in the rebamipide group. One had stomach pain, 4 had
abdominal distension, 2 had lower abdominal pain, and 5 had intractable diarrhea in the misoprostol group.S.-H. Park et al.
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found in 8/176 (4.5%) subjects in the rebamipide group and
7/156 (4.4%) in the misoprostol group. The cumulative
incidences of peptic ulcer in the rebamipide and misoprostol
groups did not differ (Odds ratio: 0.98, p = 0.9796) (Table 3).
Gastric mucosal damage, as evaluated by modified Lanza
score, did not differ between the misoprostol and rebamipide
groups (p = 0.2284) (Table 3). The high-risk subgroup
included patients with age more than 65 years, concurrent
anticoagulation treatment, history of peptic ulcer or bleeding,
concurrent corticosteroid therapy, and more than double the
standard dose of NSAID. The cumulative incidence of peptic
ulcer in this subgroup was 4.0% for rebamipide and 3.9% for
misoprostol. Prevention of NSAID-induced peptic ulcer did
not differ between the rebamipide and misoprostol groups
(Table 4).
Cumulative incidences of dyspeptic and abdominal symptoms
Diarrhea was the most frequent adverse event, and was
significantly more common in the misoprostol group (21.2%)
than in the rebamipide group (1.9%). Lower abdominal pain
and bloating were significantly more common in the miso-
prostol group than in the rebamipide group, (7.7% vs. 14.8%,
p = 0.0228 and 10.1% vs 20.7%, p = 0.00229). The cumulative
incidence of dyspeptic and abdominal symptoms such as
diarrhea and lower abdominal pain in the rebamipide group
was significantly lower than in the misoprostol group (Table 5).
Table 1. Demographic characteristics of enrolled patients
Characteristics Rebamipide Misoprostol p value
Number 207 203
Sex (M:F) 54:153 67:136 0.1244
Age (mean ± SE) 48 ± 11 46 ± 12 0.3754
H. pylori-positive 48.5% 41.7% 0.2342
Pre MLS 0 128 137
0.2633
13 8 2 9
22 7 1 7
31 2 1 5
41 5
50 0
Countries China 86 88
Korea 76 77
Thailand 45 38
MLS: modified Lanza score, statistical analysis by chi-square test











Diclofenac 75 mg/day 75 (36.2) 76 (37.4) 151 (36.8)
n.s.
Aceclofenac 100 mg/day 86 (41.5) 57 (28.1) 143 (34.9)
Naproxen 500 mg/day 13 (6.3) 19 (9.4) 32 (7.8)
Sulindac 100 mg/day 6 (2.9) 10 (4.9) 16 (3.9)
Ibuprofen 400 mg/day 5 (2.4) 7 (3.4) 12 (2.9)
Fenoprofen 600 mg/day 3 (1.4) 5 (2.5) 8 (2.0)
Mixed 19 (9.1) 29 (14.3) 48 (11.7)
Mixed: More than 2 NSAIDs
Statistical analysis by chi-square test (n.s.: not significant)
Table 3. Effects of rebamipide on endoscopic appearance of NSAID-induced gastric mucosal
injury
Rebamipide 
n = 176 (%)
Misoprostol 
n = 156 (%)
OR (95% CI) p value
Gastric ulcer 7 (3.9) 3 (1.9) 0.47 (0.10–1.73) 0.2847
Duodenal ulcer 1 (0.5) 4 (2.5) 4.60 (0.67–90.54) 0.1741
Peptic ulcer 8 (4.5) 7 (4.4) 0.98 (0.33–2.81) 0.9796
MLS 0/1/2 99/25/23 (83.5) 102/26/12 (89.7)
0.2284
MLS 3/4/5 18/4/7 (16.5) 13/0/3 (10.3)
OR: Odds ratio
95%CI: 95% Confidence Interval
Ulcer: A and H stage ulcer onlyRebamipide and Misoprostol: Multicenter RCT-STORM
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Discussion
NSAIDs are widely used for the relief of pain and
inflammation in patients with rheumatoid arthritis or other
inflammatory diseases. NSAIDs, which can induce gastro-
pathies such as dyspepsia and epigastric pain due to peptic
ulceration, can unfortunately worsen the quality of life
of patients, and result in serious, life-threatening ulcers.
NSAIDs inhibit prostaglandin synthesis; this is the principal
mechanism responsible for both their anti-inflammatory
effects and gastrointestinal toxicity. Inhibition of PG
synthesis abrogates a number of PG-dependent mucosal
defense mechanisms such as mucosal blood flow and
bicarbonate secretion [11].
This study has certain limitations: it was not performed in
double-blind fashion, and multiple agents rather than a single
agent were used. The main reason we performed a placebo
study instead of a comparative study is that it was difficult to
obtain permission to perform the study from the Ethics
Committees of each center of the three Asian countries
involved. In addition, 12-week administration resulted in a
relatively high drop-out rate: 33 patients (15.9%) in the
rebamipide group and 48 patients (23.6%) in the misoprostol
group. The major reason for patient drop-out was request by
patients for discontinuation of participation in the study: 20.9%
of patients discontinued the study since they exhibited
improvement and therefore no longer needed administration
of NSAIDs. This was followed by low level of compliance
with test drugs, and abdominal symptoms. In particular, 16
subjects (including 12 patients in the misoprostol group)
dropped out due to interaction of dyspeptic and abdominal
symptoms (Fig. 2).
In this study, 6 NSAIDs were administered at the
minimum daily dose. If subjects were administered less than
minimum daily dose, they were not included in analysis due
to low level of drug compliance. Various NSAIDs were used
in each center in Korea, China, and Thailand. Thus, a total
of 6 types of NSAIDs with similar propensity to induce
gastrointestinal complications were used in this study.
The subjects of this study included patients who re-started
administration of NSAIDs after more than 4 weeks of
discontinuation of NSAIDs, as well as those who received
Table 4. Effect of rebamipide on endoscopic appearance of NSAID-induced gastric
mucosal injury in high-risk subjects
Rebamipide 
n = 151 (%)
Misoprostol 
n = 154 (%)
OR(95%CI) p value
Gastric ulcer 5 (3.3) 2 (1.3) 0.38 (0.05–1.81) 0.2574
Duodenal ulcer 1 (0.7) 4 (2.6) 3.99 (0.58–78.68) 0.2174
Peptic ulcer 6 (4.0) 6 (3.9) 0.97 (0.30–3.19) 0.9723
OR: Odds ratio
95%CI: 95% Confidence Interval
Ulcer: A and H stage ulcer only
Table 5. Cumulative incidences of dyspeptic and abdominal symptoms determined from
patients diaries







Diarrhea 4 (1.9) 43 (21.2) <.0001
Low abdominal pain 16 (7.7) 30 (14.8) 0.0228
Low abdominal symptoms 20 73 <.0001
Nausea 20 (9.7) 20 (9.9) n.s.
Bloating 21 (10.1) 42 (20.7) 0.0029
Satiety 19 (9.2) 18 (8.9) n.s.
Fullness 21 (10.1) 32 (15.8) n.s.
Vomiting 5 (2.4) 9 (4.4) n.s.
Epigastric pain 28 (13.5) 40 (19.7) n.s.
Acid regurgitation 11 (5.3) 11 (5.4) n.s.
Total dyspeptic symptoms 125 172 0.0509
Total 145 245 0.0083
Statistical analysis by chi-square test (n.s.: not significant)S.-H. Park et al.
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NSAIDs for the first time. Patients who had been taking
NSAIDs were excluded from the study, since they were
vulnerable to dyspepsia, and this could make it difficult to
clearly determine the incidence of dyspepsia, the purpose of
this study.
Several studies have been performed in attempts to identify
agents that can be coadministered to prevent NSAID-induced
ulcers and ulcer complications. Recently, administration of
proton pump inhibitors has been reported to be associated
with acceleration of ulcer healing and prevention of ulcer
relapse among long-term users of NSAIDs [12, 13]. Repeated
use of the synthetic prostaglandin misoprostol as a form of
replacement therapy has been shown to prevent NSAID-
induced gastroduodenal ulcers and reduce the incidence of
life-threatening ulcer complications [3,  10]. Misoprostol
features poor compliance and adverse effects such as
diarrhea, abdominal pain, and nausea during administration
[14]. In our study, the misoprostol group had more adverse
events such as diarrhea, abdominal pain, and bloating than
did the rebamipide group. These adverse effects of miso-
prostol suggest that rebamipide is more useful for prevention of
NSAID-induced gastrointestinal complications. These findings
suggest that strong suppression of acid secretion and
increase in PG production were effective in preventing
NSAID-induced gastric ulcers.
For these reasons, we performed the present randomized,
multicenter, controlled study of rebamipide and misoprostol.
Both of these agents stimulate PG biosynthesis. In this study,
the incidences of NSAID-induced peptic ulcer in the miso-
prostol and rebamipide groups were equivalent (Odds Ratio:
0.98, 95%CI = 0.33-2.81, p = 0.9796). The number of cases
of gastric ulcer in the rebamipide group was seven, although
this group included two patients with serious mucosal
damage before initiation of the trial (grades 3 and 4, as
determined using modified Lanza score). In this study,
patients were relatively young, with a mean age in the
rebamipide group of 48 and in the misoprostol group of 46
years. This was one of the reasons for the relatively low rates
of induction of gastric ulcer in this trial. The high-risk group
was defined to include patients with age above 65 years,
concurrent use of anticoagulation, history of peptic ulcer or
bleeding, concurrent use of corticosteroid therapy, and/or
high-dose administration of NSAIDs >2 times. The results
for this group are shown in Table 4, and were similar to
those for the group of all patients.
In addition, rebamipide was better tolerated than miso-
prostol. The cumulative incidence of dyspeptic symptoms in
the rebamipide group was significantly lower than that in
the misoprostol group (diarrhea p<0.0001, low abdominal
pain  p = 0.0228, and bloating p = 0.00229, respectively).
Rebamipide stimulates the production of endogenous PGs [6].
This finding demonstrated the importance of PG induction in
the prevention of NSAID-induced gastric ulcer. Blood flow is
known to be regulated by prostaglandins. In our preliminary
study on the prevention of ibuprofen-induced gastrointestinal
complications for healthy volunteers, rebamipide did not
decrease blood flow in the antrum [15].
In conclusion, in this randomized, multicenter, controlled
trial, rebamipide prevented peptic ulcers as effectively as
misoprostol in patients on long-term NSAID therapy. In
addition, rebamipide decreased low abdominal symptoms
more significantly than misoprostol. Rebamipide may thus
be a useful therapeutic option for the prevention of NSAID-
induced gastrointestinal ulcer because of its therapeutic
effect and safety.
Acknowledgments
This study was supported by a grant from Korea OIAA
(Otsuka International Asia Arab) Co., Ltd., Seoul, Korea.
Other investigators participating in this study
Xin-Guang Liu, De-An Tian, and He-Sheng Luo from
China and Varocha Mahachai and Ong-ard Praisontarangkul
from Thailand.
References
[1] Maetzel, A., Ferraz, M.B., and Bombardier, C.: The cost-
effectiveness of misoprostol in preventing serious gastro-
intestinal events associated with the use of nonsteroidal
anti-inflammatory drugs. Arthritis Rheum., 41, 16–25, 1998.
[2] Raskin, J.B., White, R.H., Jackson, J.E., Weaver, A.L.,
Tindall, E.A., Lies, R.B., and Stanton, D.S.: Misoprostol
dosage in the prevention of nonsteroidal anti-inflammatory
drug-induced gastric and duodenal ulcers: a comparison of
three regimens. Ann. Intern. Med., 123, 344–350, 1995.
[3] Silverstein, F.E., Graham, D.Y., Senior, J.R., Davies, H.W.,
Struthers, B.J., Bittman, R.M., and Geis, G.S.: Misoprostol
reduces serious gastrointestinal complications in patients
with rheumatoid arthritis receiving nonsteroidal anti-
inflammatory drugs. Ann. Intern. Med., 123, 241–249, 1995.
[4] Elliott, S.L., Yeomans, N.D., Buchanan, R.R.C., and Smallwood,
R.A.: Efficacy of 12 months’ misoprostol as prophylaxis
against NSAID-induced gastric ulcers. Scand. J. Rheumatol.,
23, 171–176, 1994.
[5] Yamasaki, K., Ishiyama, H., Imaizumi, T., Kanbe, T., and
Yabuchi, Y.: Effect of OPC-12759, a novel antiulcer agent,
on chronic and acute experimental gastric ulcer, and gastric
secretion in rats. Jpn. J. Pharmacol., 49, 441–448, 1989.
[6] Arakawa, T.: Rebamipide, a novel prostaglandin-inducer,
accelerates healing and reduces relapse of acetic acid-
induced rat gastric ulcer: comparison with cimetidine. Dig.
Dis. Sci., 40, 2469–2472, 1995.
[7] Zea-Iriarte, W.L., Makiyama, K., Goto, S., Murase, K., Urata,
Y., Sekine, I., Hara, K., and Kondo, T.: Impairment of anti-
oxidants in colonic epithelial cells isolated from trinitrobenzeneRebamipide and Misoprostol: Multicenter RCT-STORM
Vol. 40, No. 2, 2007
155
Sulphonic acid-induced colitis rats. Scand. J. Gastroenterol.,
31, 985–992, 1996.
[8] Tarnawski, A., Arakawa, T., and Kobayashi, K.: Rebamipide
treatment activates epidermal growth factor and its receptor
expression in normal and ulcerated gastric mucosa in rats:
one mechanism for its ulcer healing action? Dig. Dis. Sci.,
43, 90S–98S, 1998.
[9] Naito, Y., Yoshikawa, T., Iinuma, S., Yagi, N., Matsuyama, K.,
Boku, Y., Fujii, T., Yoshida, N., Kondo, M., and Sasaki, E.:
Rebamipide protects against indomethacin-induced gastric
mucosal injury in healthy volunteers in a double-blind, placebo-
controlled study. Dig. Dis. Sci., 43, 83S–89S, 1998.
[10] Graham, D.Y., White, R.H., Moreland, L.W., Schubert, T.T.,
Katz, R., Jaszawski, R., Tindall, E., Triadafilopoulos, G.,
Stromatt, S.C., and Teoh, L.S.: Duodenal and gastric ulcer
prevention with misoprostol in arthritis patients taking
NSAIDs. Misoprostol Study Group. Ann. Intern. Med., 119,
257–262, 1993.
[11] Gronbech, J.E. and Lacy, E.R.: Role of gastric blood flow in
impaired defense and repair of aged rat stomachs. Am. J.
Physiol., 269, G737–G744, 1995.
[12] Hawkey, C.J., Karrasch, J.A., Szczepanski, L., Walkar, D.G.,
Barkun, A., Swannell, A.J., and Yeomans, N.D.: Omeprazole
compared with misoprostol for ulcers associated with non-
steroidal antiinflammatory drugs: Omeprazole versus Miso-
prostol for NSAID-Induced Ulcer Management (OMNIUM)
Study Group. N. Engl. J. Med., 338, 727–734, 1998.
[13] Yeomans, N.D., Tulassay, Z., Juhasz, L., Racz, I., Howard,
J.M., van Rensburg, C.J., Swannell, A.J., and Hawkey, C.J.:
A comparison of omeprazole with ranitidine for ulcers
associated with nonsteroidal antiinflammatory drugs. Acid
Suppression Trial: Ranitidine versus Omeprazole for NSAID-
associated Ulcer Treatment (ASTRONAUT) Study Group.
N. Engl. J. Med., 338, 719–726, 1998.
[14] Weaver, A.L. and Gitlin, N.: Ulcer prevention in long-term
users of nonsteroidal anti-inflammatory drugs. Arch. Intern.
Med., 162, 2248–2249, 2002.
[15] Kim, H.K., Kim, J.I., Kim, J.K., Han, J.Y., Park, S.H., Choi,
K.Y., and Chung, I.S.: Preventive effects of rebamipide on
NSAID-induced gastric mucosal injury and reduction of
gastric mucosal blood flow in healthy volunteers. Dig. Dis.
Sci., In press, 2007.